Clinical Trial Update: A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures [Phase 2]

View source ↗

Summary

This Phase 2 study compares NPT 2042 to placebo in patients aged 16-75 years with genetic generalized epilepsy and absence seizures and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Absence Seizures
• Genetic Generalized Epilepsy

Drugs mentioned

• NPT 2042

Snippet

Sponsor: NeuroPro Therapeutics, Inc. | Conditions: Epilepsy, Generalized, Epilepsy, Absence | Phase 2 | Status: RECRUITING